Topics
Glioblastoma | Treatment | Clinical trials | Vaccines
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Vaccines
Galanis E, Dooley KE, Keith
Anderson S, Kurokawa CB, Carrero XW, Uhm JH, Federspiel MJ,
Leontovich AA, Aderca I, Viker KB, Hammack JE, Marks RS, Robinson
SI, Johnson DR, Kaufmann TJ, Buckner JC, Lachance DH, Burns TC,
Giannini C, Raghunathan A, Iankov ID, Parney IF.
Carcinoembryonic
antigen-expressing oncolytic measles virus derivative in recurrent
glioblastoma: a phase 1 trial.
Nat
Commun. 2024 Jan
12;15(1):493. doi:
10.1038/s41467-023-43076-7. PMID:
38216554. Interventional
study. ˍ
Muragaki
Y, Ishikawa E, Tamura M, Kawamata T, Gosho M, Hashimoto K, Komori
T, Yokoo H, Matsutani M, Maebayashi K, Tanaka T, Yamaguchi S,
Kanamori M, Yamamoto T, Hanihara M, Arakawa Y, Sasayama T, Abe T,
Nakamura H, Mukasa A, Uzuka T, Nakajo K, Ohno T.
A
randomized, placebo-controlled phase III trial of an autologous,
formalin-fixed tumor vaccine for newly diagnosed glioblastoma:
trial protocol.
Jpn
J Clin Oncol.
2025 May 16:hyaf078. doi:
10.1093/jjco/hyaf078. PMID:
40377260. Interventional study protocol˰ ˍ
Bota DA, Piccioni DE, Duma CM, Kesari S, Carrillo JA, LaRocca RV,
Aiken RD, Taylor TH, Abedi M, Robles RM, Godding K, Keirstead HS,
Nistor GI, Dillman RO.
Phase 2 trial
of personal dendritic cell vaccines in newly diagnosed
glioblastoma: 3-year follow-up and correlations with survival.
Hum
Vaccin Immunother. 2025 Sep 12;21(1):2556591. doi:
10.1080/21645515.2025.2556591. PMID:
40938661. Interventional study. ˍ
Jha R, Spanehl L, Chen JA, Gessler FA, Arnaout O, Valdes PA, Choi
BD, Peruzzi PP, Bernstock JD, Chiocca EA.
Translational
advancements in tumor vaccine therapies for glioblastomas.
Neurooncol
Adv. 2025 Sep 9;7(Suppl 4):iv72-iv83. doi:
10.1093/noajnl/vdaf051. PMID:
40933034. Review. ˍ
Chen
HC, Wong ET, Sarangi S, Elinzano H, Kuburich NA, Mani SA, Ali R,
Cielo D, Svokos KA, Sampath P, Malik AN, Lee CK, Doberstein CE,
Lawler SE, Seyhan A, El-Deiry WS, Chen CC.
Tumor
antigen only (TAO) vaccine platforms for glioblastoma
therapeutics: a systematic review of evidence from clinical
trials.
EClinicalMedicine.
2026 Feb 26;93:103774. doi:
10.1016/j.eclinm.2026.103774. PMID:
41783089. ˍ
Kunz
EM, Foster DT, Durrani A, Kioutchoukova IP, Thakkar R, Davidson C,
Foreman M, Lucke-Wold B.
Active
immunization strategies in glioblastoma - clinical outcomes and
effect modifiers for dendritic vaccines and adoptive cell
therapies: a systematic review.
J
Clin Neurosci.
2026 Mar 14;148:111983. doi:
10.1016/j.jocn.2026.111983. PMID:
41833230˰ ˍ
Georges
JF, Clay C, Amin S, Goralczyk A, Mossop C, Bilbao CJ, Valeri A,
Ifrach J, Zaher M, Colman L, Kohler L, Schumann EH, Vu M, Burns
BA, Trivedi A, Liu W, Namekar M, Hofferek CJ, Ernste KJ, Bisht N,
Vazquez-Perez J, Oyewole-Said D, Amanya SB, Rodriguez V, Kraushaar
DC, Okoebor D, Bellayr I, Hartenbach J, Halpert MM, Duus EM,
Aguilar LK, Hsu SH, Zhu JJ, Zvavanjanja RC, Bai Y, Kang SW, Jang
HJ, Lee HS, Garg R, Esquenazi Y, Tandon N, Turtz A, Konduri V,
Decker WK.
Phase
I Clinical Study of DOC1021 (dubodencel) for Adjuvant
Immunotherapy of Glioblastoma.
medRxiv
[Preprint].
2026 Apr 2:2026.03.28.26349013. doi:
10.64898/2026.03.28.26349013. PMID:
41959823. Trial
registration ID:
NCT06805305. ˍ
Garfinkle
EAR, Perales-Linares R, Gimple RC, Livingstone AJ, Roberts KF,
Butt OH, Goedegebuure SP, McLellan MD, Chang GS, Hundal J, Yan J,
Navarro JB, Paxton SA, Chattopadhyay S, Cooch N, Perales-Puchalt
A, Stavroulaki K, Rochestie S, Peters J, Junker B, Campian JL,
Chheda MG, Chicoine MR, Kim AH, Willie JT, Zipfel GJ, Dowling JL,
Miller CA, Griffith OL, Griffith M, Gillanders WE, Miller KE,
Mardis ER, Sardesai NY, Dunn GP, Johanns TM.
Adjuvant
personalized multivalent neoantigen DNA vaccination for MGMT
unmethylated glioblastoma: a phase 1 trial.
Nat
Cancer.
2026 May 12. doi:
10.1038/s43018-026-01163-w. PMID:
42120910. Trial
registration ID:
NCT04015700. ˍ
Hashii
Y, Fujisaki H, Terashima K, Goto H, Horibe K, Sugiyama K,
Takahara-Matsubara M, Goto M, Yanagisawa T, Kikuta A, Kawamoto H,
Hashimoto N, Oka Y, Sugiyama H, Hara J.
Phase
1/2 study of a WT1 peptide-dosing emulsion in pediatric patients
with recurrent/refractory diffuse intrinsic pontine glioma,
glioblastoma, or anaplastic astrocytoma.
Eur
J Cancer.
2026 May 19;242:116808. doi:
10.1016/j.ejca.2026.116808. PMID:
42176363. Trial
registration ID:
NCT02750891˰ ˍ
Ozer
BH, Lindhorst SM, Merrell RT, Trevino CR, Rudnick JD, Avgeropoulos
NG, Ramakrishna N, Khagi S, Rauf Y, Walbert T, Pan E, Youssef M,
Fink KL, Mandel JJ, Taylor LP, Colman H, Dunbar EM, Paleologos N,
Burton EC, Wu J, Leeper HE, Gonzalez J, Penas-Prado M, Raizer JJ,
Veglia E, Craig S, Yuan Y, Chambers C, Wall K, Grajkowska E,
Mendoza T, Armstrong TS, Gilbert MR.
Pembrolizumab,
Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma
Post-Chemoradiation: Results from a Multi-institutional, Phase 2,
Randomized, Placebo-Controlled Trial.
medRxiv
[Preprint].
2026 Jun 24:2026.06.22.26354817. doi:
10.64898/2026.06.22.26354817. PMID:
42396282. Trial
registration ID:
NCT03018288. ˍ
Bunse
L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A,
Breckwoldt MO, Harting I, Sahm F, Schlenk RF, Schmitt A, Schnell
O, Hense J, Misch M, Krex D, Denk M, Walz J, Steinbach JP, von
Deimling A, Schmitt M, Bunse T, Tabatabai G, Bendszus M, Poschke
I, Wick W, Platten M.
IDH1-mutant
vaccine in newly diagnosed astrocytoma: final analysis of the
multicenter, single-arm, open-label, first-in-human phase 1 NOA16
trial.
Nat
Cancer.
2026 Jul 1. doi:
10.1038/s43018-026-01199-y. PMID:
42387024. Trial
registration ID:
NCT02454634. ˍ